洛曼妥珠单抗

洛曼妥珠单抗
单克隆抗体
种类?
目標RSPO3
臨床資料
其他名稱OMP-131R10
ATC碼
  • 未分配
识别信息
CAS号1684393-04-1
ChemSpider
  • none
UNII
KEGG
化学信息
化学式C6456H9954N1714O2048S46
摩尔质量145,825.36 g·mol−1

洛曼妥珠单抗（INN：rosmantuzumab[1]；开发代号：OMP-131R10）是一种靶向RSPO3的人源化单克隆抗体，设计用于治疗癌症。[2][3][4]

该药物由OncoMed（英语：OncoMed）制药开发。[5]

参考资料

  1. ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115 (PDF). WHO Drug Information. 2016, 30 (2) [2024-03-24]. （原始内容存档 (PDF)于2018-02-05）. 
  2. ^ Katoh M. Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review). Int. J. Mol. Med. August 2018, 42 (2): 713–725. PMC 6034925 可免费查阅. PMID 29786110. doi:10.3892/ijmm.2018.3689. 
  3. ^ Katoh M. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). Int. J. Oncol. November 2017, 51 (5): 1357–1369. PMC 5642388 可免费查阅. PMID 29048660. doi:10.3892/ijo.2017.4129. 
  4. ^ Katoh M, Katoh M. Molecular genetics and targeted therapy of WNT-related human diseases (Review). Int. J. Mol. Med. September 2017, 40 (3): 587–606. PMC 5547940 可免费查阅. PMID 28731148. doi:10.3892/ijmm.2017.3071. 
  5. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Rosmantuzumab （页面存档备份，存于互联网档案馆）, American Medical Association.